Republic Services, Inc. (RSG)
NYSE: RSG · Real-Time Price · USD
231.21
+0.56 (0.24%)
At close: Aug 1, 2025, 4:00 PM
233.19
+1.98 (0.86%)
After-hours: Aug 1, 2025, 7:05 PM EDT
Oncternal Therapeutics Stock Forecast
Stock Price Forecast
The 20 analysts that cover Oncternal Therapeutics stock have a consensus rating of "Buy" and an average price target of $255.95, which forecasts a 10.70% increase in the stock price over the next year. The lowest target is $200 and the highest is $284.
Price Target: $255.95 (+10.70%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Oncternal Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 7 | 7 | 7 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 9 | 8 | 7 | 7 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 19 | 19 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $280 → $284 | Buy | Maintains | $280 → $284 | +22.83% | Jul 30, 2025 |
| UBS | UBS | Hold Maintains $250 → $260 | Hold | Maintains | $250 → $260 | +12.45% | Jul 30, 2025 |
| Raymond James | Raymond James | Buy Maintains $257 → $260 | Buy | Maintains | $257 → $260 | +12.45% | Jul 22, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $250 → $260 | Hold | Maintains | $250 → $260 | +12.45% | Jul 18, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $262 → $268 | Buy | Maintains | $262 → $268 | +15.91% | Jul 9, 2025 |
Financial Forecast
Revenue This Year
17.03B
from 16.03B
Increased by 6.25%
Revenue Next Year
17.95B
from 17.03B
Increased by 5.37%
EPS This Year
6.95
from 6.49
Increased by 7.12%
EPS Next Year
7.72
from 6.95
Increased by 11.04%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.8B | 19.1B | 20.9B | ||
| Avg | 17.0B | 17.9B | 19.0B | ||
| Low | 16.4B | 17.3B | 18.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.9% | 12.0% | 16.6% | ||
| Avg | 6.3% | 5.4% | 5.9% | ||
| Low | 2.3% | 1.5% | 1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.33 | 8.46 | 9.41 | ||
| Avg | 6.95 | 7.72 | 8.60 | ||
| Low | 6.43 | 7.30 | 8.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.9% | 21.7% | 21.9% | ||
| Avg | 7.1% | 11.0% | 11.5% | ||
| Low | -0.9% | 5.0% | 4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.